Thursday, 2 June 2016

The Future of Neuroscience Education

I spent the majority of my career in medical education and saw significant changes over time.

One encouraging sign was the emergence of neuroscience as a respected and beneficial academic discipline.

Now, a new perspective on Neuroscience Training for the 21st Center has been written by Huda Akil and colleagues. This perspective is recently published in the journal Neuron with free access to the full-text manuscript.

Here are my notes from reading this perspective. Readers can access the free full-text manuscript by clicking on the link in the citation below.

Two important challenges for the field

  • Incorporating data and statistical skills traininng in neuroscience
  • Integration of other scientific disciplines in neuroscience research (engineering, CS)

Need to improve trainee skills in high-level programming languages (i.e. MATLAB)

Enhanced communication skills in training are needed to address publication and grant-writing challenges

Improvement is needed in "enabling the process by which basic science discoveries add fundamental knowledge to the field and inform solutions for disabiling neurological and psychiatric conditions". 

The above goal can be met by integrating collaborative training of basic and clinical neuroscience trainees.

Neuroscience trainees will need to be trained to meet demands of job availability
Number of neuroscience Ph.Ds graduate greatly exceed number of academic faculty slots
Federal research funding is unable to meet needs of many neuroscience graduates
However, non-academic private positions in neuroscience are expanding providing optimism for many neuroscience Ph.Ds

Key roles exist in multiple sectors to attract and train the best and brightest
  • Academia
  • Private sector
  • Societies and Patient-Advocacy Organizations
  • NIH, NSF and other funding agencies

These agencies must plan and work together to "ensure the success of this next generation of neuroscientists"

My Commentary
This is an outstanding summary of the challenges and opportunities for neuroscience education. As a physician I am particularly excited about clinical opportunities for integrating basic neuroscience training the the medical setting. I have recently been thinking about how a name change for neurology and psychiatry might aid in this evolution. Stay tuned for a provocative post on a new integrated neuroscience medicine discipline.

Follow me on Twitter WRY999

Photo of brown thrasher is from my personal file collection.

Akil, H., Balice-Gordon, R., Cardozo, D., Koroshetz, W., Posey Norris, S., Sherer, T., Sherman, S., & Thiels, E. (2016). Neuroscience Training for the 21st Century Neuron, 90 (5), 917-926 DOI: 10.1016/j.neuron.2016.05.030

Wednesday, 1 June 2016

Pain Prevalence in Dementia

The development of speech and language impairment in dementia presents barriers in many clinical domains.

One important clinical domain is assessment and management of pain. Dementia may preclude spontaneous or interview-elicited pain reporting.

A report today in MedicalXpress noted reduced reporting of pain in patients with diabetes and cognitive impairment.

I was able to locate one free full-text manuscript reviewing the prevalence of pain in various types of dementias. This literature review found the following:

  • Pain prevalence was estimated at 46% of Alzheimer's disease patients
  • Pain prevalence was estimated at 56% of vascular dementia patients
  • Pain prevalence was estimated at 53% in mixed dementia patients
  • Insufficient research study was found for determining rates of pain in frontotemporal and Lewy body dementia populations

These studies support rigorous pain assessment and monitoring for pain in dementia patient populations. Alert clinicians and nurses can aid in proxy assessment of pain when speech and language impairments reduce pain self reporting.

You can access this full text review manuscript by clicking on the PMID in the citation below.

I found a helpful education sheet produced by the Australian government on pain in dementia. This sheet included a list of potential non-verbal signs of pain in later stages of dementia including:
  • Facial grimacing
  • Moaning or crying out with movement
  • Increased heart rate, blood pressure or sweating
  • Changes in sleep patterns including increased or restless sleep
  • Changes in behavior including increased irritability or aggression.

You can access the Pain and Dementia Education in the Dementia Q&A section at this link. 

Follow the author on Twitter HERE

Photo of ring-billed gull in flight is from my files.

van Kooten J, Binnekade TT, van der Wouden JC, Stek ML, Scherder EJ, Husebø BS, Smalbrugge M, & Hertogh CM (2016). A Review of Pain Prevalence in Alzheimer's, Vascular, Frontotemporal and Lewy Body Dementias. Dementia and geriatric cognitive disorders, 41 (3-4), 220-32 PMID: 27160163

Tuesday, 31 May 2016

The Promise of DTI (Imaging) in Neurology

Brain diffusion tensor imaging (DTI) is emerging as new important brain imaging tool in research.

Clinicial applications of DTI are lagging the research applications in development.

However, clinical applications are coming.

The Radiological Society of North America recently published a summary of potential application for DTI in Neurology on their website. You can access the website post HERE.

Three key areas were highlighted in this post including use of DTI for:
  • Aiding Identification of Prognosis in Mild TBI
  • Gender Effects on Sports-Related Head Injury
  • Brain Mapping Neurosurgery

Included at the website are two You Tube Videos. Here is the video related to using DTI as a prognostic aid in TBI.




Dr. ML Lipton featured in the You Tube video has a free full-text published a study of DTI in soccer heading in the manuscript cited below. Click on the PMID to get to the manuscript.

In this manuscript the authors were able to identify change in white matter brain microstructure related to prevalence of soccer heading independent of concussion.

Image of white matter corona radiata is my screen shot from the iPad app Brain Tutor.

Follow me on Twitter WRY999

Lipton ML, Kim N, Zimmerman ME, Kim M, Stewart WF, Branch CA, & Lipton RB (2013). Soccer heading is associated with white matter microstructural and cognitive abnormalities. Radiology, 268 (3), 850-7 PMID: 23757503






Friday, 27 May 2016

Prenatal Smoking and Offspring Schizophrenia

The topic prevention of brain disorders  is commonly neglected. This is despite increasing evidence for evidence-based support for prevention opportunities.

This issue is highlighted in a recent study out of Finland that examined prenatal nicotine metabolite levels and offspring diagnosis of schizophrenia.

In this study, Solja Niemela and the Finnish research team examined all live births in Finland between 1983 and 1998.

What makes this study powerful is the measurement of maternal serum cotinine levels in maternal serum during the early and mid stages of prenancy. Cotinine is a metabolite and the levels of cotinine reflect the level of nicotine consumption.

The key findings from this study include the following points:

  • Measuring cotinine levels as a continuous variable yielded an increased odds ratio for schizophrenia of 3.41 (95% CI 1.86-6.24)
  • Mothers in the highest cotinine level group had a 38% increase in offspring schizophrenia rates
  • These findings included controlling for potential confounding variables including maternal age and parental history of psychiatric disorders

Interestingly a PubMed search found a second study linking maternal smoking with increased risk of offspring diagnosis of bipolar disorder (odds ratio 2.01, 95% CI 1.48-2.53).

These two studies in combination support a potential non-specific effect of prenatal nicotine exposure on risk for two of the most impairing psychiatric disorders. 

These two studies also support aggressive smoking cessation efforts in young women before pregnancy or at the latest very early after conception.

You can find more information about these two studies by clicking on the citation links below.

Follow the author on Twitter WRY999

Photo of pair of pin-tail ducks is from my files.

Niemelä, S., Sourander, A., Surcel, H., Hinkka-Yli-Salomäki, S., McKeague, I., Cheslack-Postava, K., & Brown, A. (2016). Prenatal Nicotine Exposure and Risk of Schizophrenia Among Offspring in a National Birth Cohort American Journal of Psychiatry DOI: 10.1176/appi.ajp.2016.15060800

Talati A, Bao Y, Kaufman J, Shen L, Schaefer CA, & Brown AS (2013). Maternal smoking during pregnancy and bipolar disorder in offspring. The American journal of psychiatry, 170 (10), 1178-85 PMID: 24084820

Thursday, 26 May 2016

Free Alcohol Use Reduction App

An investigational app and online program to reduce alcohol intake is now available free to the public.

This tool is an application of cognitive bias modification. A link to a study supporting cognitive bias modification is noted in the citation below. Click on the PMID link to get to the abstract.

The program uses a 15 minutes per day tool for four days.

The program was developed at the London School of Economics by Professor Paul Dolan.

Users who sign up to use the tool will be providing data to further determine the effectiveness of the app.

Read more about this tool at Science Daily HERE.

A link to the program and app can be found HERE.

Follow me on Twitter @WRY999 HERE.

Photo of painting titled "Peasants Enjoying a Beer at Pub in Fribourg" is from Wikipedia Creative Common file. Citation: By François Louis Jaques (1877–1937) (Beurret & Bailly) [Public domain], via Wikimedia Commons

Gladwin TE, Rinck M, Eberl C, Becker ES, Lindenmeyer J, & Wiers RW (2015). Mediation of cognitive bias modification for alcohol addiction via stimulus-specific alcohol avoidance association. Alcoholism, clinical and experimental research, 39 (1), 101-7 PMID: 25623410

Wednesday, 25 May 2016

A New Chromosome Y Risk for Alzheimers

There are many risk factors for Alzheimer's Disease (AD) including history of head trauma and family history of AD.

The strongest risk factor is advanced age. Yearly risk for AD is about 1% per year in 70 year old populations jumping to around 7% in 90 year old groups.

Now a recent study is shedding some light on a new risk for AD in men. This risk appears to be related to a chromosome Y phenomenon known to be associated with aging.

Elderly men show a tendency to lose the Y chromosome from a small percentage of cells over time. This phenomenon is known as loss of Y or LOY.

The percentage of blood cells with LOY can be determined. A study recently published in Journal of Human Genetics (see citation below) found significant support for higher percentage of LOY being linked to AD risk.

Here are the key findings:

  • In a sample of 3218 elderly men 17% showed evidence of LOY chromosome mosaicism
  • LOY percentage rates were strongly positively correlated with older age
  • Men with AD had higher rates of LOY than age-matched men without AD (adjusted odds ratio=2.80)
  • Two prospective studies found higher rates of incident AD in men with LOY (adjusted odds ratio=6.80)

These findings are not simply minor as the effect of LOY on risk appears similar in magnitude to the strongest genetic risk factor for AD, APOE gene status.

LOY has also been linked to a higher risk of cancer, so it appears to be a non-specific risk factor.

The authors of this study note;
"Regardless of the underlying mechanism(s) for the increased risk of AD and cancer in men with LOY in blood, our and other's published results reinforce a role of factors on chromosome Y in various, still poorly explored biological processes, other than sex determination and sperm production."
LOY is not yet a common test in clinical practice. However, I think we will be hearing much more on this association with potential for screening and intervention studies.

Access the free full-text manuscript by clicking on the DOI link in the citation below.

Follow me on Twitter WRY999

Photo of eastern screech owl is from my photo files.

d sperm production.
Dumanski JP et al (2016). Mosiac loss of chromosome Y in blood is associated with Alzheimer's disease American Journal of Human Genetics : 10.1016/j.ajhg.2016.05.014

Tuesday, 24 May 2016

Does Flu Vaccination Reduce Dementia Risk?

In my daily review of neuroscience news I ran across an article flu vaccination and dementia risk in heart failure.

This study was reported at the 3rd World Congress on Acute Heart Failure by Dr. Ju-Chi Liu from Taipei Medical University.

So how might influenza vaccination be related to dementia risk?  We do know acute influenza infection reaches the brain causing headache and increasing brain inflammation, at least temporarily. We also know brain inflammation may be involved in the mechanism of amyloid and tau protein deposition in the brain. So this link has some potential biological plausibility.

In the Taiwanese study, 20,509 subjects with a diagnosis of heart failure were followed via centralized records. About half received flu vaccination during follow up. Subjects receiving at least one flu vaccination had a 35% lower rate of dementia diagnosis compared to those not receiving any vaccination. Subjects receiving three or more vaccinations had a 55% lower risk of recorded dementia diagnosis on follow up.

I went to PubMed looking for more research for this association and a similar finding has been published by the same research group in a free full-text manuscript in patients with chronic kidney disease (CKD). The key elements of this study were:

  • Subjects: All 32,844 individuals with a chronic kidney disease diagnosis in the Taiwan National Health Insurance Research Database. From this set 11,843 subjects had sufficient data for the study.
  • Case definition: Influenza vaccination during the study period
  • Outcome definition: Research database definition of dementia during follow up period
  • Results: After controlling for confounding variables, influenza vaccination case subjects had a 36% lower rate of dementia diagnosis compared to those not vaccinated (odds ratio=.64)

Interestingly, there appeared to be a dose dependent effect with those receiving multiple influenza vaccinations showing even lower rates of dementia.

Also, somewhat unexpectedly, vaccinations given outside of the typical influenza season showed a greater effect.

The authors note in their discussion:
"In clinical practice, we suggest that CKD patients with high dementia risk be vaccinated."
The authors note dementia risk is increased in CKD with hypertension, high blood cholesterol and diabetes.

The most important potential implication in these two studies, is whether influenza might reduce dementia risk in the general non-medically ill population. I think we will have more research on this issue soon.

There are many reasons for regular influenza vaccination. Preserving brain health may be another important reason for expanded vaccination efforts.

You can access the free full-text manuscript of the CKD and dementia paper by clicking on the PMID link in the citation below.

Follow me on Twitter WRY999

Figure of influenza virus in post is from Wikipedia Creative Commons file authored by: National Institutes of Health; originally uploaded to en.wikipedia by TimVickers (), transferred to Commons by Quadell using CommonsHelper

Liu JC, Hsu YP, Kao PF, Hao WR, Liu SH, Lin CF, Sung LC, & Wu SY (2016). Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients: A Population-Based Cohort Study. Medicine, 95 (9) PMID: 26945371

Tuesday, 19 July 2011

Autism and MRI Physical Biomarkers

Minor physical anomalies (MPAs) commonly occur in those with autism.  I have previously published a post on a study outlining the type and prevalence of these anomalies in a series of case of autism and austim spectrum disorder.

One of the MPAs noted in the 1970s in autism spectrum disorder is an increased intraorbital distance (distance between the eyes).   This abnormality also noted as hypertelorism has been noted in a variety of brain developmental abnormalities as well as in some normal individuals.

The brain developmental correlates of hypertelorism have not been studied extensively.  It is possible that developmental hypertelorism may reflect brain developmental variations linked to clinical disorders.

Cheung et al and colleagues from the University of Hong Kong and Harvard School of Dental Medicine recently published a brain MRI study of intraorbital distance in autism spectrum disorder in PloS One.  This study examined the correlation of intraorbital distance with a variety of brain structural measurements.

Thirty six children between the ages of 7 and 16 years with autism spectrum disorder were compared to a group of 55 developmentally normal children matched by age and gender.  The two groups were in the normal intelligence range with the verbal IQ of the autism spectrum group 112 compared to a verbal IQ of 117 in the control group.

Magnetic resonance imaging scans were used to accurately measure the intraorbital distance.  This measurement was then compared with brain structure volumes.

Intraorbital distance correlated with several brain regions volumes in the autism spectrum group but not in the control group.  The areas with increased volume correlating with intraorbital distance in the autism spectrum group included:
  • Bilateral amygdala
  • Bilateral medial temporal lobe regions
  • Left inferior frontal cortex lobes
Amygdala developmental abnormalities have previously been noted in studies of autism.  The medial lobe appears to be important in social and language skills developments.

The authors note the possible relationship between intraorbital distance and brain development in this statement from the manuscript discussion section: 

     "The inference is that in this group, the growth of midline bony and brain regions are tightly linked; that is, regions involved in the regulation of socialization, emotion and memory appear to enlarge with the visual system".

These finding suggest that MRI intraorbital distance may be a potential biomarker for autism spectrum disorders.   Additional longitudinal studies of intraorbital distance and brain development in children may provide additional support for the findings in this cross-sectional studies.

Image of intraorbital distance measurement in autism from Cheung et al distributed under the terms of Creative Commons Attributions License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 

Cheung C, McAlonan GM, Fung YY, Fung G, Yu KK, Tai KS, Sham PC, & Chua SE (2011). MRI study of minor physical anomaly in childhood autism implicates aberrant neurodevelopment in infancy. PloS one, 6 (6) PMID: 21687660

Wednesday, 13 July 2011

Why Antidepressants Can Cause Gut Pain

Selective serotonin reuptake inhibitors frequently produce significant gastrointestinal side effects.  Nausea was reported by up to 26% of subjects and diarrhea in up to 30% of subjects in a recent review of the new antidepressant vilazodone.  Gastrointestinal side effects tend to be seen with the initiation of antidepressant drugs commonly followed by a period of improved tolerability.

The mechanism for this gastrointestinal effect is poorly understood.   The gut is known to have serotonin receptors.  Some gastrointestinal therapeutic agents target the serotonin receptor as their mechanism of action.  For example, the antinausea drug ondansetron appears to act through it's antagonism of the 5HT (serotonin) 3 receptor.  This results in inhibition of gastric activity while components of activity of the small intestine remain functional.

To better understand the effects of serotonin on GI motility, Janssen and colleagues from the University of Leuven conducted a novel experiment.  Twenty healthy subjects were studied in a GI motility study following administration of placebo and the selective serotonin reuptake inhibitor citalopram.

The authors found that administration of citalopram significant reduced the gastrointestinal transit time compared to that found at baseline and placebo (see chart).

Upper gastrointestinal transit time is composed of three separate phases known as the migrating motor complex of MMC.  Citalopram appeared to reduce the duration of phase 1 and phase 2 while the time spent in phase 3 was unchanged.

The authors attribute the change in transit time to a direct effect of citalopram on GI serotonin receptors although a central CNS effect could not be ruled out.  The speculate this effect may be potentially therapeutic in individuals with constipation predominant irritable bowel syndrome.

This study did not directly address the issue of GI side effects associated with the SSRI antidepressants.  Nevertheless, it suggests acute increased GI transit times with SSRIs may be a mechanism that contributes to GI side effects of nausea, diarrhea, cramping and pain.

Further studies of this effect are needed looking at a longer time frame.  Since most GI side effects improve with prolonged administration, it is possible a receptor compensation mechanism may be involved in changes in side effects over time.

Graph of gastrointestinal transit times is an original graph produced by the author from data in the manuscript.

Janssen P, Vos R, & Tack J (2010). The influence of citalopram on interdigestive gastrointestinal motility in man. Alimentary pharmacology & therapeutics, 32 (2), 289-95 PMID: 20456311

Tuesday, 12 July 2011

New Exercise Guidelines Add Neuromotor Domain

Article first published as New Exercise Guidelines Are Here on Technorati.

The American College of Sports Medicine (ACSM) recently published an update on their recommendations for exercise.  These guidelines follow an extensive review of the research literature and update guidelines that were previously published in 1998.

The guidelines note four specific areas of exercise: cardiorespiratory fitness and reduction in risk of cardiovascular and metabolic disease, maintenance of muscular fitness, flexibility and neuromotor fitness.

The guidelines provide a very extensive review of exercise research.  I will summarize the key recommendations by area of exercise:

Cardiovascular fitness and reduction in risk of cardiovascular and metabolic risk factors:

  • Moderate intensity aerobic exercise for 30 minutes per day on five or more days per week or
  • Vigorous intensity aerobic exercise for 20 minutes per on three or more days per week or
  • A combination of moderate and vigorous aerobic exercise resulting in a total energy expenditure of 500 to 1000 MET minutes per week
The MET (metabolic equivalent of task) minutes per week is a method of quantifying exercise.   By definition, the amount of energy needed at rest is one MET.  Moderate intensity is assigned activities such as walking that can be rated in the 3 to 6 MET range.  Vigorous exercise (such as jogging or running) is rated at MET levels about 6.  A person walking at a 4 MET level for 200 minutes per week would expend 1000 MET minutes in a week meeting the exercise guidelines

Muscular fitness
Resistance training for each of the major muscle groups two or three times per week

Flexibility
Complete a series of flexibility exercises two or more days per week (60 seconds per each of the major muscle and tendon groups

Neuromotor Exercise
Exercise focusing on balance, agility and coordination for 20 minutes on two or more days per week

The benefits and recommendations have been expanded in this version of the ACSM guidelines.  The authors note the growing literature supporting the benefits of exercise such as tai chi and yoga in promoting balance and flexibility.  Balance and flexibility become increasingly important to counteract the effects of aging.  There is more research support for these types of exercise programs to reduce risk of falls and fall-related medical complications in older individuals.

The ACSM notes the limited compliance with exercise guideline compliance in the general population.  Although walking is ranked as the more frequency physical activity in adults, less than 10% of walkers meet the weekly guideline threshold for duration and intensity.

The ACSM makes some recommendations to increase compliance with the guidelines:

  • Patients and their physicians should work together to develop and monitor customized programs
  • Use behavioral strategies of "goal setting, social support, reinforcement, problem solving and relapse prevention
  • Further research targeting factors promoting maintenance of exercise compliance over extended periods
The ACSM has provided a valuable to put together a comprehensive exercise program with benefits in many areas.  Now it's time for more individuals to adopt a healthy lifestyle that includes meeting these recommended guidelines.

Photo of women getting exercise by walking from the author's private collection.

Garber, C., Blissmer, B., Deschenes, M., Franklin, B., Lamonte, M., Lee, I., Nieman, D., & Swain, D. (2011). Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults Medicine & Science in Sports & Exercise, 43 (7), 1334-1359 DOI: 10.1249/MSS.0b013e318213fefb

Monday, 11 July 2011

Cannabis Use Declines with Aerobic Exercise

Improvement in addiction treatment interventions in needed.  Many substance dependence individuals end up with with a chronic illness with frequent relapse following periods of abstinence.

Aerobic exercise appears to be a candidate for a treatment component in a variety of addictive disorders.  Aerobic exercise may produce a variety of changes in the brain that may influence craving and drug use.

Mechanisms induced by aerobic exercise that might influence drug craving and drug use include:

  • Alteration in the brain reward circuit
  • Increased release of brain dopamine and changes in dopamine receptor sensitivity
  • Decrease in anxiety and depressive symptoms 
Maciej Bukowski and colleagues at Vanderbilt University recently published a trial of cannabis craving and use in a series of subjects.  Regular cannabis user were enrolled in a ten session intervention that included ten 30 minute supervised treadmill periods.  Subjects exercised at 60% of their calculated maximum heart rate. 

All subjects met DSM-IV criteria for cannabis dependence.  Subjects were not involved in any formal substance abuse treatment program and did not express a desire to reduce or discontinue their cannabis use.  Subjects were using an average of 33.5 standard joint equivalents of cannabis at the beginning of the study.  The average daily cannabis use of the subjects is displayed in the plot below taken from the manuscript:



The plot demonstrates a significant reduction in daily cannabis use during the active aerobic exercise period. Daily joint use dropped from approximately six joints per day to an average of about two to three joints per day during the exercise period.  Following completion of the exercise phase, daily joint use climbed up again approaching the run-period levels.

This study was not done in a treatment-seeking sample.  It is unclear whether a similar effect would be seen in treatment seeking samples.  The study did not include a control sample.  Nevertheless, this study should stimulate research in treatment samples.  It suggests that regular aerobic exercise may be a valuable component of treatment for cannabis dependence.  Extended aerobic exercise may be valuable in the longer term reduction of cannabis use in those with cannabis dependence.

Chemical model of tetrahydrocannabinol (the psychoactive substance in cannabis) from the Creative Commons file at Wikipedia authored by Ben Mills.

Cannabis use Creative Commons Attribution License plot from Plos One manuscript authored by Maciej Bukowski and colleagues referenced below.

Buchowski MS, Meade NN, Charboneau E, Park S, Dietrich MS, Cowan RL, & Martin PR (2011). Aerobic exercise training reduces cannabis craving and use in non-treatment seeking cannabis-dependent adults. PloS one, 6 (3) PMID: 21408154

Thursday, 7 July 2011

More Time In Bed Boosts Basketball Performance

Looking for that extra edge on the basketball court?  Want to increase your free throw percentage and gain an extra step in quickness?  Is it a new performance enhancing drug or training technique?  No, a new study suggests it may be as easy as spending a few extra hours in bed.

Cheri Mah and colleagues from Stanford University and the University of California, San Francisco recently published their research on sleep and athletic performance in the journal Sleep.  They introduce the study by noting that extensive research documents the adverse effect of limited sleep.  However, little research examines the effect of increased sleep on performance.  Their study objective was to do just that.

Members of the Stanford University mens basketball team were recruited for the study.  The study took place over two seasons and included a baseline period of usual sleep patterns.  Then the intervention group extended their sleep pattern with a goal of a minimum of 10 hours in bed daily.

Compliance with this intervention was measured through sleep journals and actigraphy.  Actigraphy is accomplished by a wrist device that is worn and measures movement.  From this data the total sleep time can be estimated.  Sleep journal data and activity data estimated the increase in total daily sleep time to be between 100 and 150 minutes of additional sleep during the intervention period.

Athletes in the intervention groups were tested on a variety of psychometric and basketball performance skills during the baseline and intervention period.  The results of the intervention were pretty impressive.  Here is a summary of the improvement noted in the study:

  • Free throw percentage increased by 11%
  • Three point percentage increased by 14%
  • Sprint test time decreased by 4%

Other psychometric variables were improved including a reduction in time on the Psychomotor Vigilance Task, a reduction in the Epworth Sleepiness Scale score and improvement on multiple components of the Profile of Mood States including ratings of fatigue, depression and tension.

The authors note the study has some significant limitations in research design.  Only eleven athletes received the intervention.  Subjects were not blinded as to the intervention and it is possible a some of the improvement came from an expectancy effect.  Travel schedules made it difficult to assure compliance with the 10 hours in bed intervention for every day of the study.

However, this study does suggest that many athletes may be performing in the context of ongoing sleep deprivation.  Forcing compliance with an extended sleep duration holds promise of improving performance on the basketball court.  This effect appears to occur in the context of subjective improvement in psychological function.

If I were an NCAA basketball athlete, I would send a copy of this study to my coach and training staff.  Athletes now have some research to support the importance of getting plenty of sleep to achieve peak performance.

Photo of Los Angeles Clipper Player Blake Griffin Shooting Free Throw Courtesy of Tim Yates

Mah CD, Mah KE, Kezirian EJ, & Dement WC (2011). The Effects of Sleep Extension on the Athletic Performance of Collegiate Basketball Players. Sleep, 34 (7), 943-950 PMID: 21731144

Wednesday, 6 July 2011

Autism Spectrum: Why Boys Are At Higher Risk

It is no secret gender plays a key role in the risk for a variety of childhood developmental disorders. Discussion of this issue is often difficult as biases in how boys and girls are raised and evaluated can contribute to confusion. Nevertheless, research progresses in explaining why boys are more likely to develop autism spectrum condition (ASC) and other neurodevelopmental abnormalities.

Baron-Cohen and colleagues from the UK and US recently summarized some of the potential mechanisms for male predominance in autism spectrum. They note a significant male predominance in a group of childhood neurodevelopmental disorders in addition to ASC:

  • ADHD
  • Conduct disorder
  • Developmental reading disorders (dyslexia)
  • Specific language impairment
  • Tourette Syndrome

They note rates for ASC in boys is 4:1 compared to girls and for full autism is estimated as high as 11:1.

The authors note that predominance of ASC and other neurodevelopmental disorders in boys may be an “extreme expression of the male brain”. This concept states that boys and girls brains begin to differ early in the uterus. These differences result in different strengths and weaknesses. ASC may be an example of the male brain development gone too far.

Females appear to have a stronger drive to empathize (identify and respond to the feelings of others) while the male brain appears to have a stronger drive to systemize (analyze and construct rule based systems). The ASC as extreme male brain theory would propose the ASC brain is just the prototypical male brain gone to far in masculinization.

Males typically have three surges of the male hormone or androgen testosterone. The first surge occurs between 2 and 6 months in the uterus. This surge if felt to be responsible for brain masculization. The second surge occurs in the first six months of life and the third and final surge occurs in adolescence around puberty. If ASC is an example of the extreme male brain, then the fetal testosterone surge might be expected to be higher in those with ASC.

Progress in this front has evolved by comparing fetal testosterone levels with a variety of cognitive, behavioral and and emotional traits. Among normal children the following relationships have be discovered:

Positive associations with fetal testosterone levels (high levels with higher evidence of trait)

  • Autistic traits
  • Restricted or reduced interests
  • Tendency to systemize
  • Rightward asymmetry of brain corpus callosum (isthmus)

Negative associations with fetal testosterone (high levels with lower evidence of trait)

  • Amount of eye contact
  • Quality of social relationships
  • Vocabulary size
  • Empathy

Studies in those with ASC also appear to support the extreme brain hypothesis. Ten genes related to sex steroid synthesis, transport or metabolism have been linked to ASC or empathy traits. Testosterone levels tend to be higher in males with ASC than those without. Research in progress is likely to provide additional information on the merit of the extreme male brain hypothesis

The authors note there are other theories that might be supported in future research on the gender ratio in ASC. Two of these theories stem from differences in the X and Y chromosome.

A better understanding of why boys are at higher risk of ASC and autism is important. Such understanding might provide insight into avenues for early diagnosis and treatment.

Molecular model of the chemical structure of testosterone from Wikipedia Creative Commons file by Ben Mills. 


Baron-Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B, & Knickmeyer R (2011). Why are autism spectrum conditions more prevalent in males? PLoS biology, 9 (6) PMID: 21695109

Thursday, 30 June 2011

Brain Posts Cracks Technorati Top Ten: Thanks!

I try to minimize self-promotion on this blog but today I'm going to do a little of that.  I started this blog nearly two years ago for personal motivation to stay current with research in the clinical neurosciences.  Blogging about recent research in clinical neuroscience kept me scanning PubMed abstracts directed to my Google Reader and kept me focused on succinctly summarizing work I felt was important.  Additionally, as I approach the end of my career, I felt a non-commercial blog might be a way give something back to my profession that has given so much to me.

Like many bloggers I follow my page views to see topics that might track more than typical interest.  I follow some of the blog ranking sites to gain perspective on Brain Posts.  This last week I was pleased to see that the Technorati algorithm ranked Brain Posts as the tenth ranked blog in the Family category and 40th in the Health category.  Technorati follows over 14,000 blogs in the Family category and over 15,000 blogs in the Health category.  I am very humbled and flattered by this recognition.


I don't understand the ranking algorithms (or their validity).  The numbers seem to jump around quickly and frequently.  But I do know that followers accessing the site and referencing the site play a key role in the rankings.  So this is really a post to thank those of you who have been visitors, commenters and post links to the site.

I plan to continue posting on clinical neuroscience research topics over the next year.  Additionally, I will be putting together some of the posts into electronic book formats.  This will involve selecting posts that might be of interest to specific reader groups.  Look for compilations of Brain Posts into eBooks formats under some of the following titles:

  • Brain Science for Physicians
  • Brain Science for Parents
  • Brain Science for Teachers

Thanks again to all!

Wednesday, 29 June 2011

Vilazodone: A Novel Antidepressant

Vilazodone was approved by the Food and Drug Administration in the U.S. earlier this year, but is just now becoming available in pharmacies for prescription use.  The drug is marketed in the U.S. under the trade name Viibyd.  It is novel in that it the only antidepressant that combines two mechanisms that can increase serotonin in the brain cortex: selective serotonin reuptake inhibition and partial agonism of the 5HT1A receptor.  There are multiple selective serotonin reuptake inhibitors, i.e. fluoxetine (Prozac), sertraline (Zoloft), and escitalopram (Lexapro).  

There are also compounds that have an agonistic effect on the 5HT1A receptor.  These include:
Antidepressants: trazodone, nefazodone
Antianxiety drugs: buspirone
Atypical antipsyhotics: aripiprazole, ziprasidone, clozapine, asenapine
Illicit drugs/compounds: MDMA (ecstasy), LSD, psylocybin, cannabidiol (cannabis)
Antimigraine compounds: ergotamine
Other compounds: yohimbine

The combination of SSRI and 5HT1A agonist effect may synergistically increase serotonergic transmission.  

Two published clinical trials on vilazodone are available on PubMed.  The table below summarizes some of the key findings from the two published trials.


The dose of vilazodone studied was 40 mg in both studies.  Because of the common occurrence of gastrointestinal side effects, doses are typically initiated at a smaller level and increased to 40 mg over the first week or so.  The pattern and prevalence of gastrointestinal side effects with vilazodone appears similar to levels seen in previous SSRI trials.  Although headache was commonly reported with vilazodone, the rate did not differ from the rate endorsed by placebo.  Dizziness, dry mouth, insomnia and abnormal dreaming were endorsed at a higher level with vilazodone but by less than 10% of the subjects.

Although vilazodone was statistically superior to placebo on almost all depression measures, it was not statistically superior in remission rates in the Kahn study.  This finding along with the relatively low absolute response rate of 27.3% in the vilazodone group is a little disappointing.

The response and remission rates found in these two studies were similar to SSRIs.  Head to head comparison with an SSRI would be informative to see if vilazdone has any effectiveness or adverse event superiority.  Sexual side effects are common with the SSRIs and the two randomized vilazodone studies reported no difference in sexual side effects between vilazodone and placebo.  Additionally, the Rickels study showed some evidence for anxiety symptom reduction.  Clinical trials examining the effectiveness of vilazodone for anxiety disorders will likely be soon completed.

Disclosure:  The author has no stock in the parent company of vilazodone (Forest Labs).  Additionally no honoraria or research grant support has been received related to this drug.  The author received no reimbursement for writing this post and the comments are entirely those of the author.

Information on the agonists for the 5HT1A receptor obtained from Wikipedia.

Chemical molecular structure of vilazodone from Creative Commons file at Wikepedia by author Meodipt.


Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, & Reed CR (2009). Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry, 70 (3), 326-33 PMID: 19284933


Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, & Reed CR (2011). A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. The Journal of clinical psychiatry, 72 (4), 441-7 PMID: 21527122